• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

水飞蓟素:揭示其在肝脏疾病中的药理作用谱及治疗潜力——一项全面的叙述性综述

Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases-A comprehensive narrative review.

作者信息

Jaffar Hafiza Madiha, Al-Asmari Fahad, Khan Faima Atta, Rahim Muhammad Abdul, Zongo Eliasse

机构信息

University Institute of Diet & Nutritional Sciences, Faculty of Allied Health Sciences The University of Lahore Lahore Pakistan.

Department of Food and Nutrition Sciences, College of Agricultural and Food Sciences King Faisal University Al-Ahsa Saudi Arabia.

出版信息

Food Sci Nutr. 2024 Feb 16;12(5):3097-3111. doi: 10.1002/fsn3.4010. eCollection 2024 May.

DOI:10.1002/fsn3.4010
PMID:38726410
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11077231/
Abstract

Liver diseases, encompassing conditions such as cirrhosis, present a substantial global health challenge with diverse etiologies, including viral infections, alcohol consumption, and non-alcoholic fatty liver disease (NAFLD). The exploration of natural compounds as therapeutic agents has gained traction, notably the herbal remedy milk thistle (), with its active extract, silymarin, demonstrating remarkable antioxidant and hepatoprotective properties in extensive preclinical investigations. It can protect healthy liver cells or those that have not yet sustained permanent damage by reducing oxidative stress and mitigating cytotoxicity. Silymarin, a natural compound with antioxidant properties, anti-inflammatory effects, and antifibrotic activity, has shown potential in treating liver damage caused by alcohol, NAFLD, drug-induced toxicity, and viral hepatitis. Legalon® is a top-rated medication with excellent oral bioavailability, effective absorption, and therapeutic effectiveness. Its active component, silymarin, has antioxidant and hepatoprotective properties, Eurosil 85® also, a commercial product, has lipophilic properties enhanced by special formulation processes. Silymarin, during clinical trials, shows potential improvements in liver function, reduced mortality rates, and alleviation of symptoms across various liver disorders, with safety assessments showing low adverse effects. Overall, silymarin emerges as a promising natural compound with multifaceted hepatoprotective properties and therapeutic potential in liver diseases.

摘要

肝脏疾病,包括肝硬化等病症,由于多种病因,如病毒感染、酒精摄入和非酒精性脂肪性肝病(NAFLD),在全球范围内构成了重大的健康挑战。探索天然化合物作为治疗药物已受到关注,尤其是草药水飞蓟,其活性提取物水飞蓟素在广泛的临床前研究中显示出显著的抗氧化和肝脏保护特性。它可以通过减少氧化应激和减轻细胞毒性来保护健康的肝细胞或尚未遭受永久性损伤的细胞。水飞蓟素是一种具有抗氧化特性、抗炎作用和抗纤维化活性的天然化合物,已显示出治疗由酒精、NAFLD、药物诱导的毒性和病毒性肝炎引起的肝损伤的潜力。利加隆®是一种一流的药物,具有出色的口服生物利用度、有效吸收和治疗效果。其活性成分水飞蓟素具有抗氧化和肝脏保护特性,同样,商业产品欧水飞蓟素85®通过特殊的制剂工艺增强了亲脂性。在临床试验中,水飞蓟素显示出对各种肝脏疾病的肝功能有潜在改善、死亡率降低和症状缓解,安全性评估显示不良反应较低。总体而言,水飞蓟素是一种有前途的天然化合物,具有多方面的肝脏保护特性和在肝脏疾病中的治疗潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba39/11077231/9e50e48378b6/FSN3-12-3097-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba39/11077231/252615900b26/FSN3-12-3097-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba39/11077231/52e24416fa6f/FSN3-12-3097-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba39/11077231/94233cb912f3/FSN3-12-3097-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba39/11077231/9e50e48378b6/FSN3-12-3097-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba39/11077231/252615900b26/FSN3-12-3097-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba39/11077231/52e24416fa6f/FSN3-12-3097-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba39/11077231/94233cb912f3/FSN3-12-3097-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba39/11077231/9e50e48378b6/FSN3-12-3097-g001.jpg

相似文献

1
Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases-A comprehensive narrative review.水飞蓟素:揭示其在肝脏疾病中的药理作用谱及治疗潜力——一项全面的叙述性综述
Food Sci Nutr. 2024 Feb 16;12(5):3097-3111. doi: 10.1002/fsn3.4010. eCollection 2024 May.
2
Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review.水飞蓟素作为肝脏疾病的辅助治疗:叙述性综述。
Adv Ther. 2020 Apr;37(4):1279-1301. doi: 10.1007/s12325-020-01251-y. Epub 2020 Feb 17.
3
Silymarin as an Antioxidant Therapy in Chronic Liver Diseases: A Comprehensive Review.水飞蓟素作为慢性肝病的抗氧化治疗:综述
Cureus. 2024 Aug 17;16(8):e67083. doi: 10.7759/cureus.67083. eCollection 2024 Aug.
4
Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases.水飞蓟(奶蓟草):其化学、药理和在肝脏疾病中的营养保健品用途简述。
Phytother Res. 2018 Nov;32(11):2202-2213. doi: 10.1002/ptr.6171. Epub 2018 Aug 6.
5
Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review.水飞蓟素作为抗氧化剂在慢性肝病临床治疗中的作用:叙述性综述。
Ann Med. 2022 Dec;54(1):1548-1560. doi: 10.1080/07853890.2022.2069854.
6
Phytotherapy and NAFLD--from goals and challenges to clinical practice.植物疗法与非酒精性脂肪性肝病——从目标、挑战到临床实践
Rev Recent Clin Trials. 2014;9(3):195-203.
7
Chronic Liver Disease and Silymarin: A Biochemical and Clinical Review.慢性肝病与水飞蓟素:一项生化与临床综述
J Clin Transl Hepatol. 2020 Dec 28;8(4):454-458. doi: 10.14218/JCTH.2020.00012. Epub 2020 Oct 16.
8
New therapeutic potentials of milk thistle (Silybum marianum).水飞蓟(奶蓟)的新治疗潜力。
Nat Prod Commun. 2013 Dec;8(12):1801-10.
9
Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years.水飞蓟素/水飞蓟宾与慢性肝病:多年的结合
Molecules. 2017 Jan 24;22(2):191. doi: 10.3390/molecules22020191.
10
Hepatoprotective mechanism of on nonalcoholic fatty liver disease based on network pharmacology and experimental verification.基于网络药理学和实验验证的 对非酒精性脂肪性肝病的肝保护作用机制。
Bioengineered. 2022 Mar;13(3):5216-5235. doi: 10.1080/21655979.2022.2037374.

引用本文的文献

1
Effects of silymarin on liver function, antioxidant and immune factors of broilers under immune stress.水飞蓟素对免疫应激下肉鸡肝功能、抗氧化及免疫因子的影响
Vet Res Commun. 2025 Sep 15;49(6):313. doi: 10.1007/s11259-025-10883-w.
2
The Impact of Hybrid Bionanomaterials Based on Gold Nanoparticles on Liver Injury in an Experimental Model of Thioacetamide-Induced Hepatopathy.基于金纳米颗粒的杂化生物纳米材料对硫代乙酰胺诱导的肝病实验模型中肝损伤的影响
Biomolecules. 2025 Jul 24;15(8):1068. doi: 10.3390/biom15081068.
3
Isosilybin B: a potential novel therapeutic agent with hepatoprotective, anticancer and antifibrotic properties.

本文引用的文献

1
Biomaterials-Based Antioxidant Strategies for the Treatment of Oxidative Stress Diseases.基于生物材料的抗氧化策略治疗氧化应激疾病
Biomimetics (Basel). 2024 Jan 3;9(1):23. doi: 10.3390/biomimetics9010023.
2
Hepatoprotective Effects of Biochanin A on Thioacetamide-Induced Liver Cirrhosis in Experimental Rats.金雀异黄酮对实验性硫代乙酰胺诱导肝硬化大鼠的肝保护作用。
Molecules. 2023 Nov 15;28(22):7608. doi: 10.3390/molecules28227608.
3
Drug-induced liver injury and anti-hepatotoxic effect of herbal compounds: a metabolic mechanism perspective.
异水飞蓟宾B:一种具有肝保护、抗癌和抗纤维化特性的潜在新型治疗剂。
Discov Oncol. 2025 Aug 8;16(1):1502. doi: 10.1007/s12672-025-03380-8.
4
Exploring the potential of herbal drugs for treating liver fibrosis: a computational screening approach.探索草药治疗肝纤维化的潜力:一种计算筛选方法。
Asian Biomed (Res Rev News). 2025 Apr 30;19(2):78-85. doi: 10.2478/abm-2025-0010. eCollection 2025 Apr.
5
Mitigation of cadmium-induced hepatotoxicity by orally administered Xylopia aethiopica synthesized silver nanoparticles in rats.口服非洲胡椒合成的银纳米颗粒对大鼠镉诱导的肝毒性的缓解作用
J Mol Histol. 2025 Jun 5;56(3):187. doi: 10.1007/s10735-025-10454-y.
6
Carrier-Free Silibinin/Sorafenib Microparticles Alleviate Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Fatty Acid Metabolism.无载体水飞蓟宾/索拉非尼微粒通过调节脂肪酸代谢减轻代谢功能障碍相关脂肪性肝病
Int J Nanomedicine. 2025 May 30;20:6949-6962. doi: 10.2147/IJN.S515107. eCollection 2025.
7
Unraveling the Metabolic Pathways Between Metabolic-Associated Fatty Liver Disease (MAFLD) and Sarcopenia.解析代谢相关脂肪性肝病(MAFLD)与肌肉减少症之间的代谢途径
Int J Mol Sci. 2025 May 14;26(10):4673. doi: 10.3390/ijms26104673.
8
Are alterations needed in Silybum marianum (Silymarin) administration practices? A novel outlook and meta-analysis on randomized trials targeting liver injury.水飞蓟(水飞蓟素)的给药方法是否需要改变?针对肝损伤的随机试验的新观点和荟萃分析。
BMC Complement Med Ther. 2025 Apr 12;25(1):134. doi: 10.1186/s12906-025-04886-y.
9
Effects of Silibinin on Delaying Aging in .水飞蓟宾对延缓……衰老的作用
Antioxidants (Basel). 2025 Jan 27;14(2):147. doi: 10.3390/antiox14020147.
10
Silybin Cocrystals with Improved Solubility and Bioavailability.具有改善的溶解度和生物利用度的水飞蓟宾共晶体。
Pharmaceuticals (Basel). 2025 Jan 13;18(1):90. doi: 10.3390/ph18010090.
药物性肝损伤与草药化合物的抗肝毒性作用:代谢机制视角
Phytomedicine. 2024 Jan;122:155142. doi: 10.1016/j.phymed.2023.155142. Epub 2023 Oct 11.
4
Alleviation of acetaminophen-induced liver failure using silibinin nanoliposomes: An in vivo study.水飞蓟宾纳米脂质体减轻对乙酰氨基酚诱导的肝衰竭:一项体内研究。
Biochem Biophys Res Commun. 2023 Oct 8;676:103-108. doi: 10.1016/j.bbrc.2023.07.045. Epub 2023 Jul 21.
5
Medicinal plant molecules against hepatitis C virus: Current status and future prospect.药用植物分子抗丙型肝炎病毒:现状与展望。
Phytother Res. 2023 Oct;37(10):4353-4374. doi: 10.1002/ptr.7936. Epub 2023 Jul 12.
6
Critical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma.设计用于对抗肝细胞癌的植物源抗癌纳米颗粒的批判性综述
Pharmaceutics. 2023 May 29;15(6):1611. doi: 10.3390/pharmaceutics15061611.
7
The effect of medicinal plants on cirrhosis: A systematic review of clinical trials.药用植物对肝硬化的影响:临床试验的系统评价。
Phytother Res. 2023 Jul;37(7):3083-3096. doi: 10.1002/ptr.7816. Epub 2023 May 22.
8
The Role of Oxidative Stress in the Development and Therapeutic Intervention of Hepatocellular Carcinoma.氧化应激在肝细胞癌的发生发展及治疗干预中的作用。
Curr Cancer Drug Targets. 2023;23(10):792-804. doi: 10.2174/1568009623666230418121130.
9
Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP).营养疗法治疗非酒精性脂肪性肝病(NAFLD):国际脂质专家组(ILEP)的立场文件。
Pharmacol Res. 2023 Mar;189:106679. doi: 10.1016/j.phrs.2023.106679. Epub 2023 Feb 8.
10
Holistic Approach in the Management of Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病管理中的整体方法
Euroasian J Hepatogastroenterol. 2022 Jul;12(Suppl 1):S51-S58. doi: 10.5005/jp-journals-10018-1359.